Numerous studies in chronic lymphocytic leukaemia (CLL) have demonstrated the adverse prognostic significance of structural abnormalities of chromosomes 17p13 and 11q23, regions that encompass the TP53 and ATM genes, respectively. The identification of patients with progressive disease and a TP53 abnormality is particularly important as most are resistant to purine analogues and alkylating agents but frequently respond to alemtuzumab, which kills by a TP53-independent mechanism. Most studies, including recent large randomized trials of initial therapy for CLL, utilize interphase fluorescence in situ hybridization to detect TP53 and ATM loss. The cutoff level for TP53 loss that correlates best with clinical outcome remains controversial. Many studies have used a 3-5% cutoff based on the level of aberrant signal patterns to be expected in normal controls. However, in the UK CLL4 trial, only cases with 420% TP53 loss had a poor response to initial therapy and short progression free and overall survival.
1 TP53 loss is frequently accompanied by a mutation of the remaining allele. 2 The mutations are usually missense mutations and the mutant protein has a prolonged half-life enabling its detection by flow cytometry, western blotting or immunostaining. Less than 5% of patients have a TP53 mutation without loss of the normal allele and would not be identified if fluorescence in situ hybridization was used as the sole screening test.
The single large study in which unselected CLL patients were screened for the presence of ATM mutations found an incidence of 12%.
3 A follow-up study identified ATM mutations with deletion of the ATM gene in only 38% of patients, contrasting with the high concordance found between TP53 loss and mutation. Preliminary data suggest that the outcome of patients with an ATM mutation is poorer than for those with ATM loss without mutation. 4 Both the TP53 and ATM genes are integral to the DNA damage response pathway to double-stranded DNA breaks. Functional assays of this pathway, measuring activation of TP53 and ATM, upregulation of downstream genes or resistance to apoptosis, have been developed and have potential diagnostic and prognostic value. Carter et al. 5 measured expression of TP53 and p21, initially by western blotting, and more recently by flow cytometry before and following exposure of CLL cells to ionizing irradiation. TP53 dysfunction was defined as a failure to upregulate p21 expression following irradiation. Cases could be subdivided into those with increased basal levels of TP53 (type A) and those with low baseline TP53 expression (type B). In the initial study, there was a perfect correlation between type A dysfunction and the presence of a TP53 mutation, and type B dysfunction and the presence of an ATM mutation. However, a recent update while confirming the strong association between type A dysfunction and TP53 loss in greater than 50% of cells detected type B dysfunction in cases with TP53, ATM or 13q loss. 6 Nutlin-3a, a small-molecule inhibitor of the interaction between TP53 and MDM2, upregulates TP53 and p21 expression in cells with wild-type TP53, and can induce apoptosis alone or in combination with alkylating agents, purine analogues or topoisomerase 2 inhibitors in CLL cells in vitro. Increased apoptosis has been demonstrated in small numbers of cases with a deletion of 11q or low ATM protein levels, but not in those with a TP53 mutation.
The aim of this study was to develop a functional assay suitable for routine clinical use, capable of identifying and distinguishing abnormalities of TP53 and ATM. To achieve this, we employed a radiomimetic drug etoposide, which obviated the need for a radiation source, used alone and in combination with nutlin-3a. Forty-seven patients were selected based on a prior screen for the presence of TP53 and ATM loss by fluorescence in situ hybridization and for mutations using direct sequencing of exons 2-9 and denaturing high-performance liquid chromatography, respectively. Twelve had no detectable TP53 or ATM abnormality, 15 had TP53 loss and/or mutation and 20 had ATM loss and/or mutation (Table 1) . Cryopreserved mononuclear cells from each case were thawed and exposed to 50 mM etoposide alone, or 50 mM etoposide plus 5 mM nutlin-3a. Initially, we defined cutoff values using receiver operating characteristic analysis for the expression of TP53 and p21 following etoposide treatment. Percentage increases in TP53 and p21 expression below 30 and 15% respectively defined dysfunctional cases. Those cases in which function was Table 1 Summary of functional analysis in the ATM/TP53 molecular groups The functional status of 47 cases was assessed in relation to their ATM and TP53 status by fluorescence in situ hybridization and mutational analysis.
Letters to the Editor restored with the combination of etoposide and nutlin-3a were classified as category 2 dysfunction, while failure to restore function was classified as category 1. The combination of etoposide and nutlin-3a was better at distinguishing category 1 from category 2 dysfunction than nutlin-3a alone. In addition, we confirmed that cryopreservation did not affect functional categorization by comparing data on fresh and frozen cells from representative cases in each functional category. The responses of representative cases from each functional category are shown in Figure 1a . No dysfunction was detected in the 12 cases with no TP53 or ATM abnormality. Category 1 dysfunction was found in all 11 patients with a TP53 mutation, including 3 without TP53 loss. Category 2 dysfunction occurred in all 16 cases with an ATM mutation including 4 without ATM loss.
No dysfunction was detected in the four cases with TP53 loss or eight cases of ATM loss lacking a mutation of the remaining allele ( Table 1 ).
Factors that could potentially affect the sensitivity of the functional assay include the ability of etoposide to reliably induce double-stranded DNA breaks, especially in drug-resistant cases, the choice of TP53 and p21 expression as markers of TP53 dysfunction, the size of the mutant and deleted clones and the nature of the TP53 or ATM mutations. A comparison of etoposide and g-irradiation showed no difference in their ability to induce DNA damage or upregulation of TP53 and p21 in untreated or previously treated cases with either wild-type or mutated TP53 or ATM (data not shown). There was also a close correlation between TP53 and p21 expression measured by either flow cytometry or immunoblotting (Figure 1b) . To compare the sensitivity of the functional assay with direct sequencing for TP53 mutations and high-performance liquid chromatography for ATM mutations, we mixed varying proportions of CLL cells from patients with either a TP53 or ATM mutation and a large clone showing concomitant deletion of the same gene, with those from a patient with wild-type TP53 and ATM. Thus, the deletion was used as a surrogate marker for the size of the mutated clone, assuming that each leukaemic cell with a deletion had a mutation of the remaining allele. We were Letters to the Editor able to detect a functional defect when the deleted TP53 and ATM clone comprised 20 and 46% of the sample, respectively (Figure 2) . Mutations in the TP53 and ATM genes were detected when the respective deleted clones comprised 69 and 9.1% of the sample. These data suggest that the functional assay may be more sensitive for detecting mutations than direct sequencing, but an initial high-performance liquid chromatography screen can greatly increase the sensitivity of mutational analysis. No dysfunction was found in patients with ATM loss without a mutation detectable by high-performance liquid chromatography even when the size of the deleted clone exceeded 90%. However, the mean size of the deleted clone in cases with TP53 loss without mutation was only 13% (8.5-25) , and the presence in these cases of a small mutated clone, undetectable with direct sequencing, could not be excluded.
Interestingly, when the size of the deleted clone in the patient with TP53 loss and mutation was reduced to 15% by dilution with wild-type cells, etoposide induced upregulation of TP53 but not p21. This pattern, termed type C dysfunction, had previously been observed in patients with a p21 polymorphism, 7 but our data suggest that this pattern may indicate the presence of small TP53 mutated clone. In this study, we define a TP53 mutation as one that confers an alteration in the protein sequence. All eight cases with both TP53 loss and mutation had missense mutations within the exons encoding the DNA binding domain of the protein. Two of the three mutated cases without TP53 loss had mutations within intron 7, resulting in aberrant splicing of exons 7 and 8, as previously described. 8 The finding of dysfunction in patients with TP53 or ATM mutations without loss of the other allele might indicate that these mutations exert Assessment of the sensitivity of the etoposide/nutlin-3a assay to TP53 and ATM mutations. A case with TP53 loss and a missense mutation was diluted to the indicated TP53 loss clone sizes with cells from a case with no detectable loss or mutation. The baseline expression of TP53 (a) and the percent increase in TP53 (b) or p21 (c) expression was evaluated following exposure to 50 mM etoposide. A TP53 mutation was evident by direct sequencing in the 42% dilution. A case with ATM loss and a missense mutation was diluted to the indicated ATM loss clone sizes with cells from a case with no detectable loss or mutation. The percentage increase in (d) TP53 or (e) p21 expression was evaluated following exposure to etoposide. An ATM mutation was detectable in the 9.1% ATM loss dilution. a dominant-negative effect and that this assay is sensitive to a reduction in wild-type TP53 or ATM below a critical level.
The important practical question is whether this functional assay provides additional prognostic information compared to standard fluorescence in situ hybridization analysis for TP53 and ATM loss. Seven out of 47 patients in this study had TP53 dysfunction and either an ATM or TP53 mutation without loss of the other allele. All had progressive disease requiring early treatment. Those with category 1 dysfunction failed to respond to alkylating agents or fludarabine. Although six of these cases had other risk factors for progressive disease including unmutated VH genes or use of the VH 3-21 gene, these data would support a screening strategy able to detect TP53 and ATM mutations as well as loss.
TP53 and especially ATM mutational analysis remains the province of specialized laboratories and will detect both clinically important and unimportant mutations. The etoposide/nutlin-3a functional assay provides a rapid and widely applicable screening method for clinically relevant mutations of both genes and also, potentially, for other defects in the doublestranded DNA damage repair pathway. We report for the first time a patient who developed AML with NPM1 mutation 6 years after a JAK2-V617F þ primary myelofibrosis (PMF).
OG
In May 2000, a 61-year-old woman was referred to the Haematology Institute of University 'La Sapienza', Rome, with a high platelet count (733 000 mm À3 ) and a slight splenomegaly; the white blood cell (WBC) count and the haemoglobin level were normal. A bone marrow biopsy showed an increased number of dysplastic megakaryocytes that were arranged in clusters of 5-10 cells (Figure 1a) . At the Gomori staining, there was a marked bone marrow fibrosis; iron deposits were not visible. Based on these findings PMF was diagnosed. Retrospective analysis of the JAK2 gene status on paraffin sections 3 from the initial trephine biopsy detected the JAK2-V617F mutation in about 25% of haemopoietic cells (Figures 1b and c) . Cytogenetic studies could not be performed due to the lack of metaphases. The patient was not treated until September 2000 when, due to a rise in platelets (1 236 000 mm À3 ), she was started on hydroxyurea (1 g daily, 5 days per week), which provided optimal control of the platelet count.
In April 2006, the patient presented with anaemia (9.5 g per 100 ml) and a low WBC count (1700 mm À3 ). Bone marrow aspirate and biopsy showed 490% myeloid blasts (M1 type) and residual dysplastic megakaryocytes (Figure 2a ). Cytogenetic analysis of marrow AML cells showed a normal karyotype; BCR/ ABL rearrangement as well as FLT3-ITD and FLT3-D835 mutations was absent. Microelectronic chip analysis 4 detected a low JAK2-V617F allelic ratio of about 5%, which strongly suggested that only a small fraction of the cells harboured the JAK2-V617F mutation (Figure 2b ). Immunohistological analysis of the bone marrow biopsy showed marked infiltration (490%) by leukaemic cells that were positive for CD68 (KP1) and myeloperoxidase ( Figure 3 , top left), but negative for CD68 macrophage-restricted (PG-M1) and CD34 ( Figure 3, top right) . Notably, all AML cells showed an aberrant NPM cytoplasmic expression ( Figure 3, bottom left) , while the dysplastic megakaryocytes belonging to the PMF clone displayed
